Bromocriptine

Forty male C57BL/6 mice (6 ~ 8 weeks old) were purchased from the Experimental Animal Center of First Hospital of Jilin University. For diabetes mice model, 40 C57BL/6 mice were divided into 5 groups, 8 mice in each group. The mice from diabetic group were administered with streptozotocin (STZ, Sigma, USA) intraperitoneally at the dose of 70 mg/Kg in 0.1 M citrate buffer (CIT), and PH 4.2 ~ 4.4 every other day for 3 times. The mice from control group were injected with CIT alone and served as the vehicle controls. The blood glucose level and body weight were recorded weekly for 4 consecutive weeks. The blood glucose level was determined by a glucometer, and diabetes was confirmed by fasting blood glucose > 16.7 mmol/L. The diabetes cognitive decline was determined by the Morris maze test. Then the control group and diabetes groups were given DMSO only, the zafirlukast (Yuanye, Shanghai, China, catalog: 107753-78-6) groups were given zafirlukast at the dosage of 50 mg/kg by intraperitoneal injection, the bromocriptine groups were given bromocriptine (MedChemExpress, USA, catalog: HY-12705A) at the dosage of 12 mg/kg by intraperitoneal injection, the combination groups were given both zafirlukast and bromocriptine.

Cabergoline (HY-15296), bromocriptine (HY-12705A), SCH23390 (HY-19545A), DASA-58 (HY-19330), and pyridoxine (HY-B1328) were purchased from MedChemExpress. Quinpirole (Q111) and PTX (SAE0066) were purchased from Sigma-Aldrich. Sulpiride (S4655) and vindoline (S3970) were purchased from Selleck. Quinelorane (1519) was purchased from TOCRIS. The natural products library was purchased from TargetMol (Shanghai, China). FITC-phalloidine (YP0059) was purchased from US Everbright^®Inc.